TCRT Alaunos Therapeutics, Inc.
Healthcare$2.42+2.11%ClosedMarket Cap: $5.9M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
3.66
P/S
1970.00
EV/EBITDA
-1.35
DCF Value
$0.32
FCF Yield
-54.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-6333.3%
Operating Margin
-138166.6%
Net Margin
-136966.7%
ROE
-165.9%
ROA
-218.2%
ROIC
-321.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-1.0M | $-1.0M | $— | — |
| Q4 null | $3.0K | 100.0% | $-907.0K | $-893.0K | $— | — |
| FY null | $5.0K | 100.0% | $-4.2M | $-4.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.2M | $-1.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-1.0M | $-1.1M | $— | — |
| Q1 null | $2.0K | 100.0% | $-1.1M | $-1.1M | $— | — |
| Q4 null | $4.0K | 100.0% | $-755.0K | $-742.0K | $— | — |
| FY null | $10.0K | 100.0% | $-4.8M | $-4.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.1M | $-1.1M | $— | — |
| Q2 null | $4.0K | -4400.0% | $-1.2M | $-1.1M | $— | — |
| Q1 null | $1.0K | -100.0% | $-1.7M | $-1.7M | $— | — |
| Q4 2023 | $1.0K | -93200.0% | $-7.9M | $-7.8M | $-4.90 | — |